Physician profile
Barry Ring
NPI 1487668695
$4,788.82
in general payments reported to CMS, 2019-2025
40 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $662 · 2021: $579 · 2022: $824 · 2023: $743 · 2024: $212 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Travel and Lodging: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.32 |
| Travel and Lodging | $634.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinefrontier, INC. | $780.68 | 2025 | Sijfuse, Inspan, Nanofuse |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $698.07 | 2019-2025 | Relistor |
| Abbvie INC. | $664.44 | 2021-2025 | Ubrelvy, Qulipta |
| Orexo US, INC. | $488.97 | 2019-2025 | Zubsolv |
| Almatica Pharma LLC | $214.96 | 2021-2023 | Gralise |
| Collegium Pharmaceutical, INC. | $206.33 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $199.03 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $196.73 | 2019-2021 | |
| Pfizer INC. | $136.70 | 2019-2025 | |
| Allergan, INC. | $131.43 | 2020 | |
| Lilly USA, LLC | $109.84 | 2019-2023 | Reyvow, Emgality |
| Abbott Laboratories | $102.64 | 2025 | Proclaim |
| Idorsia Pharmaceuticals US INC | $94.69 | 2022-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $82.28 | 2020-2021 | |
| Daiichi Sankyo INC. | $70.35 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.